New Compound Combines GLP-1 and Leptin Hormones for Effective Weight Loss
Ozempic maker Novo Nordisk has developed a compound that has shown promising results in suppressing appetite and promoting weight loss in mice. This new potential therapy harnesses the power of GLP-1, a hormone that mimics the effect of eating, and activates the receptor for leptin, a hormone released by fat cells that signals the brain to stop eating when enough energy has been stored.
How it Works
The compound works by mimicking the GLP-1 hormone, making users feel full for longer, and activating the leptin receptor, which reduces food intake and body weight. This combination has shown to be more effective in promoting weight loss than individual treatments.
Research
The research was conducted in collaboration with the University of Michigan and published in the journal Science Translational Medicine. The team discovered similar neurons in rhesus monkeys that respond to signals for GLP-1 and leptin. However, they have yet to determine if humans have the same neurons that can be targeted with this therapy.
Goals of the Research
The goal of the research was not to determine the viability of this approach in humans, but to prove that this kind of molecule could produce weight loss in a mouse where leptin by itself does not. The team’s paper sets a standard for how the scientific community should explore the mechanisms of this dual approach.
Background
GLP-1 drugs are already on the market to treat obesity or Type 2 diabetes. Ozempic and Wegovy contain semaglutide, while Zepbound and Mounjaro contain tirzepatide, and Victoza has liraglutide. These drugs differ in their dosage schedules and weight loss effects.
Future Developments
Novo Nordisk is also developing a weight loss pill, amycretin, that led to 13.1% weight loss in 12 weeks during a phase 1 trial. The company is continuing to explore the potential of combining GLP-1 and leptin hormones for more effective weight loss treatments.
Conclusion
The results of this research are promising, and the combination of GLP-1 and leptin hormones shows great potential for effective weight loss. Further research is needed to determine the viability of this approach in humans and to explore its potential benefits.
Frequently Asked Questions
Q: How does the compound work?
A: The compound mimics the GLP-1 hormone, making users feel full for longer, and activates the leptin receptor, which reduces food intake and body weight.
Q: What are GLP-1 drugs already on the market?
A: Ozempic, Wegovy, Zepbound, Mounjaro, and Victoza are all GLP-1 drugs already approved for treating obesity or Type 2 diabetes.
Q: What is the goal of the research?
A: The goal of the research was to prove that a molecule combining GLP-1 and leptin could produce weight loss in mice where leptin by itself does not.
Q: What is the next step for the research?
A: Further research is needed to determine the viability of this approach in humans and to explore its potential benefits.
